Recommends USS+AFP 6 monthly, or preferably 3 monthly in cirrhotics and those at high riskRecommends contrast-CT or contrast-MRI to confirm suspicious ultrasound lesions AND for initial screening of patients with advanced cirrhosis and high suspicion of HCC developmentRecommends baseline contrast-CT or contrast-MRI obtained in all cirrhotics at presentation. Here, AFP is linked to hepatocellular carcinoma.